A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground (Q30275728)

19 August 2017

5 references

23 March 2019

22 June 2019

25 June 2019

19 September 2019

13 November 2020

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground (English)

1 reference

biomedical investigative technique

19 August 2017

2 references

19 September 2019

13 November 2020

1 reference

19 September 2019

1 reference

1 reference

13 November 2020

Shashikant Srivastava

object named as

Shashikant Srivastava

series ordinal

1

0 references

Tawanda Gumbo

object named as

Tawanda Gumbo

series ordinal

7

0 references

Soumya Swaminathan

series ordinal

5

object named as

Soumya Swaminathan

1 reference

19 August 2017

2

Devyani Deshpande

1 reference

19 August 2017

3

Jotam G Pasipanodya

1 reference

19 August 2017

6

Eric Nuermberger

1 reference

19 August 2017

Tania Thomas

4

1 reference

PMCID

5064153

19 August 2017

language of work or name

English

0 references

publication date

1 November 2016

6 references

Clinical Infectious Diseases

19 August 2017

23 March 2019

22 June 2019

25 June 2019

19 September 2019

13 November 2020

6 references

19 August 2017

23 March 2019

22 June 2019

25 June 2019

19 September 2019

13 November 2020

63

1 reference

19 August 2017

suppl 3

1 reference

19 August 2017

S75-S79

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

19 August 2017

5 references

23 March 2019

22 June 2019

25 June 2019

19 September 2019

The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism

13 November 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

The association between sterilizing activity and drug distribution into tuberculosis lesions

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Nonclinical models for antituberculosis drug development: a landscape analysis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Failed Pediatric Drug Development Trials

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Commentary: a targets framework: dismantling the invisibility trap for children with drug-resistant tuberculosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Serum drug concentrations predictive of pulmonary tuberculosis outcomes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

3 June 2018

The Monte Carlo method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Developmental pharmacology--drug disposition, action, and therapy in infants and children

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5064153

Childhood tuberculosis in the United States: shifting the focus to prevention

3 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

Impact of ontogeny on linezolid disposition in neonates and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

Single dose pharmacokinetics of linezolid in infants and children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

21 January 2018

The Monte Carlo Method

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

Biological variability and the emergence of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW472

Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27742637

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27742637

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tuberculosis in children

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27742637

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/CID/CIW472

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

PMCID

5064153